Spyre Therapeutics Stock Cash Per Share
| SYRE Stock | 27.00 0.50 1.82% |
Spyre Therapeutics fundamentals help investors to digest information that contributes to Spyre Therapeutics' financial success or failures. It also enables traders to predict the movement of Spyre Stock. The fundamental analysis module provides a way to measure Spyre Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spyre Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 49.19 | 77.09 |
Spyre | Cash Per Share |
Spyre Therapeutics Company Cash Per Share Analysis
Spyre Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Spyre Therapeutics Cash Per Share | 77.09 |
Most of Spyre Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spyre Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Spyre Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Spyre Therapeutics is extremely important. It helps to project a fair market value of Spyre Stock properly, considering its historical fundamentals such as Cash Per Share. Since Spyre Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spyre Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spyre Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Spyre Cash Per Share Historical Pattern
Today, most investors in Spyre Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spyre Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Spyre Therapeutics cash per share as a starting point in their analysis.
Spyre Therapeutics Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Spyre Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Spyre Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spyre Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spyre Therapeutics could also be used in its relative valuation, which is a method of valuing Spyre Therapeutics by comparing valuation metrics of similar companies.Spyre Therapeutics is currently under evaluation in cash per share category among its peers.
Spyre Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spyre Therapeutics from analyzing Spyre Therapeutics' financial statements. These drivers represent accounts that assess Spyre Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spyre Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 81.8M | 156.0M | 420.0M | 37.9M | 148.4M | 118.2M | |
| Enterprise Value | 69.0M | 133.5M | 335.4M | 7.7M | 44.1M | 77.9M |
Spyre Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Spyre Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Spyre Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Spyre Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 1.43 B | ||||
| Shares Outstanding | 58.71 M | ||||
| Shares Owned By Insiders | 8.80 % | ||||
| Shares Owned By Institutions | 88.30 % | ||||
| Number Of Shares Shorted | 8.25 M | ||||
| Price To Book | 9.24 X | ||||
| Price To Sales | 2,210 X | ||||
| Revenue | 886 K | ||||
| EBITDA | (242.3 M) | ||||
| Net Income | (338.79 M) | ||||
| Total Debt | 84.56 M | ||||
| Book Value Per Share | 3.34 X | ||||
| Cash Flow From Operations | (99.91 M) | ||||
| Short Ratio | 21.97 X | ||||
| Earnings Per Share | (37.90) X | ||||
| Target Price | 58.63 | ||||
| Number Of Employees | 30 | ||||
| Beta | 2.91 | ||||
| Market Capitalization | 1.59 B | ||||
| Total Asset | 341.86 M | ||||
| Retained Earnings | (764.41 M) | ||||
| Working Capital | 309.55 M | ||||
| Net Asset | 341.86 M |
About Spyre Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spyre Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out Spyre Therapeutics Piotroski F Score and Spyre Therapeutics Altman Z Score analysis. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.